Evaluation of Changes in Citalopram Prescribing Patterns Following a US Food and Drug Administration Alert: A Retrospective Cohort Study.

Conclusions: The issuance of an FDA warning did not produce observable changes in prescribing patterns of citalopram. Modifiable risk factors and optimal dosing may be targets of interventions aimed at promoting safer use of citalopram. PMID: 26137354 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/26137354?dopt=Abstract

Source: The Primary Care Companion for CNS Disorders - July 3, 2015 Category: Primary Care Tags: Prim Care Companion CNS Disord Source Type: research

More News: Celexa | Citalopram | Primary Care | Study | Warnings